Moleculin Biotech says second lab test found antiviral activity for potential COVID-19 treatment – MarketWatch

Shares of small-cap Moleculin Biotech Inc
.
MBRX, +19.09%.
skyrocketed 43% in premarket trade Tuesday, after the company stated a 2nd round of laboratory testing confirmed antiviral activity for WP11 … [+809 chars]